EPS: As of FY2025 Q2, the actual value is USD -0.51.

Cash and Marketable Securities

• As of April 30, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities totaling $251.5 million, which is expected to fund operations into 2027.

Operating Expenses

• Total operating expenses for the three months ended April 30, 2025, were $27.1 million, compared to $17.3 million for the same period in 2024. This increase was primarily due to a $10.4 million rise in research and development expenses, driven by higher manufacturing and clinical costs related to the LEGEND study and personnel-related costs.

Net Loss

• The net loss attributable to common shareholders for the three months ended April 30, 2025, was approximately $25.8 million, or $0.51 per share, compared to approximately $15.0 million, or $0.38 per share, for the same period in 2024. The increase in net loss is mainly attributed to the rise in operating expenses, partially offset by net interest income.

Total Assets and Liabilities

• Total assets as of April 30, 2025, were $266.7 million, with total liabilities of $39.4 million, resulting in total shareholders’ equity of $227.3 million.

Outlook / Guidance

• enGene plans to file a Biologics License Application (BLA) for detalimogene in mid-2026, with ongoing updates from the LEGEND study expected in the second half of 2025. The company has completed EMA Scientific Advice, indicating potential suitability for a Conditional Marketing Authorization Application, assuming a positive benefit-risk ratio.